Browse the corpus

REFERENCES Boyer EW and Shannon M, “The Serotonin Syndrome,” N Engl J Med , 2005, 352(11):1112-20. [PubMed 15784664 ] Chen LC and Ashcroft DM, “Meta-Analysis Examining the Efficacy and Safety of Almotriptan in the Acute Treatment of Migraine,” Headache , 2007, 47(8):1169-77. [PubMed 17883521 ] Freitag F, Smith T, Mathew N, et al, “Effect of Early Intervention With Almotriptan vs. Placebo on Migraine-Associated Functional Disability: Results from the AEGIS Trial,” Headache , 2008, 48(3):341-54. [PubMed 18302700 ] Goadsby PJ, Zanchin G, Geraud G, et al, “Early vs. Non-Early Intervention in Acute Migraine—‘Act when Mild (AwM)'. A Double-Blind, Placebo-Controlled Trial of Almotriptan,” Cephalalgia , 2008, 28(4):383-91. [PubMed 18294251 ] Linder SL, Mathew NT, Cady RK, et al, “Efficacy and Tolerability of Almotriptan in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Trial,” Headache , 2008, 48(9):1326-36. [PubMed 18484981 ] Mathew NT, Finlayson G, Smith TR, et al, “Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT® Early Migraine Intervention Study),” Headache , 2007, 47(2):189-98. [PubMed 17300358 ] Mazzoleni R, Kreisler A, Lucas C, et al, “Seizure After Use of Almotriptan,” Clin NeurolNeurosurg , 2008, 110(8):850-1. [PubMed 18599194 ] McEnroe JD and Fleishaker JC, “Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1DReceptor Agonist for the Treatment of Migraine,” Clin Pharmacokinet , 2005, 44(3):237-46. Topic 8919 Version 37.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1004-118.195.65.243-7F1A92C927-S244013.14]